Sinovac Biotech Ltd. (NASDAQ:SVA) is scheduled to release its Q316 earnings data on Monday, November 28th.

Sinovac Biotech (NASDAQ:SVA) last issued its quarterly earnings data on Tuesday, August 23rd. The biopharmaceutical company reported ($0.15) earnings per share for the quarter. The firm had revenue of $1.38 billion for the quarter, compared to the consensus estimate of $18.49 billion. Sinovac Biotech had a negative return on equity of 10.26% and a negative net margin of 17.94%. During the same period in the prior year, the company posted $0.02 earnings per share. On average, analysts expect Sinovac Biotech to post $-0.05 EPS for the current fiscal year and $0.05 EPS for the next fiscal year.

Earnings History for Sinovac Biotech (NASDAQ:SVA)

Shares of Sinovac Biotech Ltd. (NASDAQ:SVA) opened at 6.16 on Thursday. The company’s market capitalization is $350.72 million. The stock’s 50 day moving average is $6.05 and its 200 day moving average is $5.95. Sinovac Biotech Ltd. has a 1-year low of $4.38 and a 1-year high of $7.16.

Separately, TheStreet cut shares of Sinovac Biotech from a “hold” rating to a “sell” rating in a research note on Wednesday, August 24th.

Several institutional investors have recently modified their holdings of the stock. Credit Suisse AG boosted its position in shares of Sinovac Biotech by 48.2% in the third quarter. Credit Suisse AG now owns 89,428 shares of the biopharmaceutical company’s stock valued at $527,000 after buying an additional 29,085 shares during the last quarter. State Street Corp purchased a new position in shares of Sinovac Biotech during the second quarter valued at approximately $100,000. TFS Capital LLC boosted its position in shares of Sinovac Biotech by 86.8% in the second quarter. TFS Capital LLC now owns 24,650 shares of the biopharmaceutical company’s stock valued at $146,000 after buying an additional 11,451 shares during the last quarter. Panagora Asset Management Inc. boosted its position in shares of Sinovac Biotech by 4.7% in the second quarter. Panagora Asset Management Inc. now owns 42,816 shares of the biopharmaceutical company’s stock valued at $254,000 after buying an additional 1,929 shares during the last quarter. Finally, OMERS ADMINISTRATION Corp boosted its position in shares of Sinovac Biotech by 5.6% in the second quarter. OMERS ADMINISTRATION Corp now owns 35,700 shares of the biopharmaceutical company’s stock valued at $212,000 after buying an additional 1,900 shares during the last quarter. Institutional investors own 19.07% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Sinovac Biotech Ltd. (SVA) to Release Earnings on Monday” was first posted by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are reading this article on another site, it was stolen and reposted in violation of U.S. & international trademark & copyright laws. The original version of this article can be viewed at https://www.thecerbatgem.com/2016/11/24/sinovac-biotech-ltd-sva-to-release-earnings-on-monday.html.

About Sinovac Biotech

Sinovac Biotech Ltd. (Sinovac) is a holding company. The Company is a biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases, including hepatitis A, hepatitis B, seasonal influenza, Haemagglutinase5 Neuraminidase1 (H5N1) and Influenza A (H1N1) pandemic influenza and mumps.

5 Day Chart for NASDAQ:SVA

Receive News & Stock Ratings for Sinovac Biotech Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sinovac Biotech Ltd. and related stocks with our FREE daily email newsletter.